Septic Shock News and Research

RSS

Obese patients may have advantages in certain health situations

Although obesity is linked to a variety of health risks, new research indicates that obese patients may have an advantage over nonobese patients in certain health situations, including septic shock and acute asthma exacerbation.

22 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Nottingham scientists develop novel antimicrobial catheter

A novel antimicrobial catheter that remains infection-free for up to twelve weeks could dramatically improve the lives of long-term catheter users. The scientists who have developed the new technology are presenting their work at the Society for General Microbiology's Autumn Conference at the University of Warwick.

4 Sep 2012

Why it's hard for medicine to fix its mistakes

ProPublica offers an examination of the challenges hospitals face in adopting procedures to address medical errors.

23 Jul 2012

Experts examine host recognition of Staphylococcus and E.coli bacteria

We are surrounded by bacteria, viruses, fungi and parasites. The fact that we nevertheless do not fall prey to infections is thanks to certain cellular sensor molecules such as toll-like receptors (TLR), which recognize the molecular structure of pathogens and intercede by ensuring an often completely unnoticeable elimination of the invaders. Their immune-activating abilities were only detected in 1998, a discovery which was awarded with the Nobel Prize

21 Jul 2012

Blocking bombesin/GRP receptor improves survival in sepsis animal models

Septic shock is the most severe outcome associated with pathogen infection in the bloodstream. It is a life-threatening condition invariably leading to multiple organ dysfunctions. Currently, septic shock is one of the most frequent causes of death in intensive care units worldwide.

30 Jun 2012

Obese patients with appendix less likely to have complications after minimally invasive procedure

Obese patients who need to have their appendixes removed fare better after a minimally invasive surgical procedure rather than an open operation, according to a new study published in the July issue of the Journal of the American College of Surgeons.

27 Jun 2012

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

22 Jun 2012

Methodist receives $26.2M H&HS grant to reduce blood infections and delirium

Grants from the U.S. Department of Health & Human Services totaling $26.2 million will support work by The Methodist Hospital in Houston to reduce blood infections and delirium-caused injuries in Texas hospitals.

16 Jun 2012

New analogues effective in inhibiting NOS activity in Parkinson models

14 Jun 2012

suPAR protein can serve as marker for blood poisoning

Blood poisoning is a serious problem in medical care. Research from Malmö University in Sweden now shows that the protein suPAR, which can be used for early detection of critical cases of sepsis, is found in saliva, which opens new potential for tracking diseases.

1 Jun 2012

Researchers identify single gene that controls aging, inflammation and cancer

Researchers at NYU School of Medicine have, for the first time, identified a single gene that simultaneously controls inflammation, accelerated aging and cancer.

25 May 2012

Combination therapy does not reduce mortality rates associated with severe sepsis

Frank M. Brunkhorst, M.D., of Friedrich-Schiller University, Jena, Germany, and colleagues conducted a study to compare the effect of the antibiotics moxifloxacin and meropenem with the effect of meropenem monotherapy on sepsis-related organ dysfunction.

22 May 2012

Allergies may provide benefit by keeping away noxious environmental toxins

Yale researchers suggested Wednesday that allergies may be an outgrowth of the protective mechanism of the body to protect itself from noxious substances in the environment.

26 Apr 2012

Anti-ceramide antibody may prevent radiation gastrointestinal syndrome

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

5 Apr 2012

Woman left unattended burnt in a hospital shower

Deputy State Coroner Anthony Schapel is hearing evidence about the circumstances of Ms Proctor's death on February 22 - a week after she was first admitted. The court heard Ms Proctor was suffering from multiple illnesses including alcoholic liver disease and her mobility was severely restricted by the time she was hospitalized. She required assistance to move.

4 Apr 2012

OHRI, uOttawa to lead first stem cell therapy trial for septic shock

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock.

16 Mar 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.

12 Mar 2012